Dr Xin Jiang
Senior Research Fellow

Dr Xin Jiang

School of Biotech & Biomolecular Science

Dr. Xin Jiang is a biochemist/structural biologist working on the mechanism investigation of membrane proteins. Mentored by Prof. Yigong Shi, Xin was awarded his Ph.D. degree in 2017 from Tsinghua University, where he received systematic training in protein expression, purification, engineering, and characterization. He joined Prof. Nieng Yan's lab at Princeton University in 2018 for his postdoctoral training. During his postdoctoral period, Xin systematically revealed the molecular mechanism underlying the glucose and lactate transport cycle in human and Plasmodium. Later, Dr. Xin Jiang joined the BABS of UNSW in 2019 as a senior research fellow. 

  • Journal articles | 2021
    Peng X; Wang N; Zhu A; Xu H; Li J; Zhou Y; Wang C; Xiao Q; Guo L; Liu F; Jia ZJ; Duan H; Hu J; Yuan W; Geng J; Yan C; Jiang X; Deng D, 2021, 'Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism', PLoS Biology, vol. 19, http://dx.doi.org/10.1371/journal.pbio.3001386
    Journal articles | 2020
    Gao M; Huang J; Jiang X; Yuan Y; Pang H; Luo S; Wang N; Yao C; Lin Z; Pu D; Zhang S; Sun P; Liu Z; Xiao Y; Wang Q; Hu Z; Yin H, 2020, 'Regulation of aerobic glycolysis to decelerate tumor proliferation by small molecule inhibitors targeting glucose transporters', Protein and Cell, vol. 11, pp. 446 - 451, http://dx.doi.org/10.1007/s13238-020-00725-7

We are interested in understanding the molecular mechanism of membrane proteins and their therapeutic application. Specifically, we work on two different aspects of research fields.

The first aspect of our research interest is to reveal the function and mechanism of the plasmodium membrane proteins, followed by drug development. For instance, the plasmodium transporters play critical roles in absorbing nutrition, extruding metabolic waste, and maintaining osmotic balance. Inhibition of these membrane transport proteins can efficiently hamper the proliferation of plasmodium, which provides a novel path to cure malaria. Importantly, current clinical antimalarial agents are not targeting the membrane transporters. Therefore, the novel transporter inhibitors are promising medicines to fight against the multidrug-resistant plasmodium that increasingly threatens the campaign for malaria elimination.

The other research topic is in collaboration with senior lipid researchers in BABS. Currently, we try to understand the molecular mechanisms of several membrane proteins that play important roles in lipid and cholesterol biogenesis.